[Amyloidosis in a mixed pattern. Sensitivity to colchicine and melphalan]

Area of Science:

• Hematology
• Nephrology
• Gastroenterology

Background:

• Systemic amyloidosis can manifest in multiple myeloma, affecting multiple organs.
• Light kappa chain multiple myeloma is a specific subtype associated with amyloid deposition.
• Understanding amyloidosis pathogenesis is crucial for effective treatment strategies.

Observation:

• A case of systemic amyloidosis involving the liver, kidneys, intestines, and heart in a multiple myeloma patient is presented.
• The patient received a treatment regimen combining colchicine and Melphalan.
• Treatment involved colchicine (0.5 mg thrice daily) and Melphalan (cycles of 4 days every 6 weeks at 0.25 mg/Kg/day).

Findings:

• The patient showed minimal improvement despite the combined therapy.
• Colchicine's presumed amyloid synthesis inhibition in rats did not translate to clinical benefit in this human case.
• The combination of colchicine and Melphalan proved largely ineffective for this patient's systemic amyloidosis.

Implications:

• This case underscores the limited efficacy of current therapeutic approaches for systemic amyloidosis secondary to multiple myeloma.
• Further research into novel therapeutic targets and treatment combinations is warranted.
• The findings suggest a need to re-evaluate the role of colchicine in managing human amyloidosis associated with multiple myeloma.